GoAI
Get started
Virax Biolabs Group Limited logo

Virax Biolabs Group Limited

VRAX

NASDAQHealthcareBiotechnology

Open in GoAI

Previous close

$3.19

−$0.26 · -7.54%

Aug 21, 4:00 PM ET

VRAX company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

74

Undervalued

Momentum

26

Weakening

Sentiment

49

Mixed

Risk resilience

29

High Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Virax Biolabs Group Limited is a biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases. The company is developing T cell-based test technologies intended to support an immunology profiling platform, with potential applications in post-acute infection syndromes, including Long COVID, and other chronic conditions linked to immune dysregulation.

Industry
Biotechnology
Sector
Healthcare
Headquarters
GB
CEO
James Foster
Listed since
Jul 21, 2022
Employees
26

Market position

Day range

Current $3.19

52-week range

Current $3.19

Open
$3.51
Previous close
$3.45
Volume
120.59K
0.07× average
Average volume
1.77M
Average daily volume
Market cap
595.33K USD
Beta
1.34
Market reference 1
50-day average
$3.4157
-6.61% below average
200-day average
$6.0079
-46.90% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
-3.84M USD
EV / EBITDA
0.71×
Earnings yield
-229.74%
Free cash flow yield
-223.06%

Profitability & efficiency

Return on equity
-66.30%
Return on assets
-60.35%
Return on invested capital
-70.05%

Financial health

Current ratio
9.97×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends9803%-29160%-68123%-107085%Gross margin, FY2023: -15.94%Gross margin, FY2024: 32.34%Gross margin, FY2025: -838.21%Gross margin, FY2026: 61.90%Operating margin, FY2023: -66963.67%Operating margin, FY2024: -4153.25%Operating margin, FY2025: -97344.76%Operating margin, FY2026: -51515.17%Net margin, FY2023: -63748.32%Net margin, FY2024: -4304.81%Net margin, FY2025: -95739.17%Net margin, FY2026: -40439.10%FY2022FY2023FY2024FY2025FY2026
Gross margin FY2023 -15.94%. Gross margin FY2024 32.34%. Gross margin FY2025 -838.21%. Gross margin FY2026 61.90%. Operating margin FY2023 -66963.67%. Operating margin FY2024 -4153.25%. Operating margin FY2025 -97344.76%. Operating margin FY2026 -51515.17%. Net margin FY2023 -63748.32%. Net margin FY2024 -4304.81%. Net margin FY2025 -95739.17%. Net margin FY2026 -40439.10%.

Income trends

Revenue

12.42K USD+96.22%

Operating income

−6.4M USD-3.84%

Net income

−5.02M USD+17.12%
Income trends across reported periods845.41K USD−1.91M USD−4.67M USD−7.42M USDRevenue, FY2023: 8.56K USDRevenue, FY2024: 156.42K USDRevenue, FY2025: 6.33K USDRevenue, FY2026: 12.42K USDOperating income, FY2022: −1.73M USDOperating income, FY2023: −5.73M USDOperating income, FY2024: −6.5M USDOperating income, FY2025: −6.16M USDOperating income, FY2026: −6.4M USDNet income, FY2022: −1.71M USDNet income, FY2023: −5.46M USDNet income, FY2024: −6.73M USDNet income, FY2025: −6.06M USDNet income, FY2026: −5.02M USDFY2022FY2023FY2024FY2025FY2026
Revenue FY2023 8.56K USD. Revenue FY2024 156.42K USD. Revenue FY2025 6.33K USD. Revenue FY2026 12.42K USD. Operating income FY2022 −1.73M USD. Operating income FY2023 −5.73M USD. Operating income FY2024 −6.5M USD. Operating income FY2025 −6.16M USD. Operating income FY2026 −6.4M USD. Net income FY2022 −1.71M USD. Net income FY2023 −5.46M USD. Net income FY2024 −6.73M USD. Net income FY2025 −6.06M USD. Net income FY2026 −5.02M USD.
Metric (USD)FY2026FY2025FY2024FY2023FY2022
Revenue12.42K USD6.33K USD156.42K USD8.56K USD—
Cost of goods sold4.73K USD59.4K USD105.83K USD9.93K USD—
Gross profit7.69K USD−53.07K USD50.59K USD−1.37K USD—
Research and development3.74M USD1.78M USD1.56M USD397.11K USD433.74K USD
Selling, general, and administrative2.67M USD4.33M USD4.59M USD5.33M USD1.3M USD
Operating expenses6.41M USD6.11M USD6.55M USD5.73M USD1.73M USD
Interest income————15.44K USD
Interest expense61.77K USD58.18K USD26.88K USD15.47K USD15.44K USD
Depreciation and amortization439.02K USD343.39K USD103.1K USD1 USD1.73M USD
Operating income−6.4M USD−6.16M USD−6.5M USD−5.73M USD−1.73M USD
Net income−5.02M USD−6.06M USD−6.73M USD−5.46M USD−1.71M USD

Company facts updated Aug 24, 2026.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$1.00

68.65% downside
Past 12 months12-month forecastHigh $1.00Average $1.00Low $1.00

VRAX peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

Continue in GoAI

Research VRAX

research.disclaimer